

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

In the Claims

- 1-17. (Cancelled)
18. (Currently amended) A composition ~~for therapy~~ for reducing ~~or treating~~ restenosis of coronary or peripheral vessels comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation.
19. (Previously presented) The composition of claim 18 wherein the protein agent for inhibiting VEGF is a soluble VEGF receptor.
20. (Currently amended) The composition of claim 18 wherein the protein agent for inducing vessel maturation ~~comprises angiopoietin-1~~ is angiopoietin-1.
21. (Currently amended) The composition of claim 19 wherein the protein agent for inducing vessel maturation ~~comprises angiopoietin-1~~ is angiopoietin-1.
22. (Currently amended) A method for reducing ~~or treating~~ restenosis of coronary or peripheral vessels comprising administering ~~[[a]]~~ the composition as claimed in claim 18.
23. (Currently amended) A kit for formulating the composition of claim 18 ~~for reducing or treating restenosis~~ comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in the same container.
24. (Currently amended) A kit for formulating the composition of claim 18 ~~for reducing or treating restenosis~~ comprising a protein agent for inhibiting VEGF and a protein agent for inducing vessel maturation, wherein the agents are in separate containers.
25. (Previously presented) The kit of claim 24 wherein separate containers are in a package together.
- 26-33. (Cancelled)